Treatment with dostarlimab, an immunotherapy, showed good results in a small trial of 12 patients with rectal cancer, according to a new study, but more research is needed.

According to a study published in the New England Journal of Medicine, all 12 patients diagnosed with rectal cancer recovered after using the drug for six months.

In addition, patients did not experience any significant side effects during treatment. But it is believed that the study did not include enough participants to shed light on the various negative symptoms caused by the drug, according to a report published by The Independent.

The report added that despite their enthusiasm for the study, the scientists pointed to the need for other studies to achieve the same good results, warning against the conclusion that cancer patients were cured. of medicine.

Dustarlimab is an immunotherapy used to treat endometrial cancer, but this study is the first clinical trial to see if the drug is effective against rectal cancer tumors.

The drug works by detecting cancer cells, allowing the immune system to recognize and destroy them.